x
ServiziMenu principaleHome
Facebook Twitter Linkedin Print
Home > Studi clinici > Protocolli 2024 - in attivazione

Protocolli GOIRC-sponsored in attivazione

GOIRC-01-2022  HEROS (OSSERVAZIONALE)

HER2 aberrations in advanced NSCLC: an Observational, retrospective and prospective, multi-centric Study exploring HER2 alterations incidence and therapeutic management in Italy

Centro Coordinatore: Parma

 

GOIRC-01-2023  CARRY-ON

Continued PD-L1 inhibition with atezolizumab with rechallenge chemotherapy in patients with sensitive relapse SCLC progressing on first-line platinum-etoposide chemotherapy and a PD-L1 inhibitor – CARRY ON study

Centro Coordinatore: Bologna

 

GOIRC-01-2024 PRELUDE

Pembrolizumab plus lenvatinib in REcurrent ccRCC patients failing permbroLizUmab aDjuvant trEatment: PRELUDE Trial – GOIRC-01-2024

Centro Coordinatore: Terni

 

GOIRC-02-2024 IMMUNOSTAR

Phase II randomized trial of XELOX plus DoSTARlimab versus XELOX alone as Consolidation Treatment after Standard Chemoradiation in pMMR/MSS Locally Advanced Rectal Cancer (LARC) Patients – IMMUNOSTAR Trial – GOIRC-02-2024

Centro Coordinatore: Reggio Emilia

 

GOIRC-03-2024  REMAIN

Investigation of REcurrence Mechanisms to Adjuvant osimertINib in radically resected EGFR-mutated NSCLC patients: REMAIN study – GOIRC-03-2024

Centro Coordinatore: Parma

 

GOIRC-04-2024 CECYDE

A multicenter open-label phase II study of Cemiplimab plus chemotherapy, selected on the basis of baseline cytidine deaminase activity, in advanced squamous non-small cell lung cancer - CECYDE trial – GOIRC-04-2024

Centro Coordinatore: Lucca

 

 

Apri